{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT04310215",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CARTISTEM_2019_01"
      },
      "Organization": {
        "OrgFullName": "Hyundai Bioland Co., Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus",
      "OfficialTitle": "A Multi-center, Single-blind, Randomized, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Adding CARTISTEM® on Microfracture in Patients With Talar Chondral or Osteochondral Defect"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2021",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 3, 2020",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 2022",
        "PrimaryCompletionDateType": "Anticipated"
      },
      "CompletionDateStruct": {
        "CompletionDate": "June 2022",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 12, 2020",
      "StudyFirstSubmitQCDate": "March 16, 2020",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 17, 2020",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "June 11, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 14, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Hyundai Bioland Co., Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "Medipost Co Ltd.",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "No",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Chondral or Osteochondral Lesion of Talus"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "OLT",
          "Talus",
          "Chondral Lesion",
          "Osteochondral Lesion",
          "Human umbilical cord blood-derived stem cell",
          "MSC",
          "Mesenchymal stem cell"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 3"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignInterventionModelDescription": "A multicenter, Single-blinded, Stratified randomized",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Double",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "102",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Microfracture + CARTISTEM®",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: CARTISTEM®"
              ]
            }
          },
          {
            "ArmGroupLabel": "Microfracture",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Procedure: Microfracture"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "CARTISTEM®",
            "InterventionDescription": "*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠\n\nProcedure: Microfracture\nBiological: CARTISTEM®(Human Umbilical Cord Blood-derived Mesenchymal Stem Cell product)",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Microfracture + CARTISTEM®"
              ]
            }
          },
          {
            "InterventionType": "Procedure",
            "InterventionName": "Microfracture",
            "InterventionDescription": "*Stratified randomization by lesion size below 1.5㎠ or more than 1.5㎠\n\n1. Procedure: Microfracture",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Microfracture"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "ICRS-Cartilage Repair Assessment Total Score",
            "PrimaryOutcomeDescription": "Arthroscopic evaluation of articular cartilage repair\n\n: The score range from 12(normal) to 1(severely abnormal) where lower scores indicate more severity of injury",
            "PrimaryOutcomeTimeFrame": "Week 48"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "ICRS-Cartilage Repair Assessment Overall Grade",
            "SecondaryOutcomeDescription": "The grades range from 1(normal) to 4 (severely abnormal) where lower grades indicate more complete repair",
            "SecondaryOutcomeTimeFrame": "Week 48"
          },
          {
            "SecondaryOutcomeMeasure": "Improvement degree of Cartilage Repair by MRI",
            "SecondaryOutcomeDescription": "Changes in MOCART(Magnetic resonance Observation of Cartilage Repair Tissue) score\n\n: MOCART score is a 9-part and 29-item scoring system, also resulting in a find cartilage repair tissue score between 0 and 100 points. 100 points represent the best imaginable score",
            "SecondaryOutcomeTimeFrame": "Week 0 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Degree of Functional improvement in FAOS(Foot & Ankle Outcome Score)",
            "SecondaryOutcomeDescription": ": FAOS consists in 42 items that cover 5 dimensions (symptoms, pain, activities of daily living, sport and recreation activities, and quality of life. Raw scores of each sub-scales results of the sum of each items. A normalized score (100 indicationg no symptoms and 0 indicating extreame sysmptoms) is calculated for each subscale",
            "SecondaryOutcomeTimeFrame": "Week 0, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Degree of Functional improvement in AOFAS(The American Orthopaedic Foot & Ankle Score)",
            "SecondaryOutcomeDescription": ": AOFAS consists in 9 items that can be divided into 3 sub-scales (pain, function and alignment). 100 points of 1 to 100 represent no symptoms or impairments",
            "SecondaryOutcomeTimeFrame": "Week 0, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Degree of Functional improvement in Tegner activity score",
            "SecondaryOutcomeDescription": ": Tegner activity represents the highest level of activity on scale of 0 to 10 that you are able to participate in currently . The higher values represent a better outcome",
            "SecondaryOutcomeTimeFrame": "Week 0, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Degree of Quality of Life improvement in SF-36(Short Form Health Survey-36)",
            "SecondaryOutcomeDescription": ": SF-36 comprises 36 items divided into two components of physical health and mental health. Higher scores between 0 and 100 represent better health status",
            "SecondaryOutcomeTimeFrame": "Week 0, 24 and 48"
          },
          {
            "SecondaryOutcomeMeasure": "Degree of pain improvement in 100 mm VAS(Visual Analogue Scale)",
            "SecondaryOutcomeDescription": "VAS represents higher scores mean higher pain\n0 mm (no pain) and 100 mm (worst pain)",
            "SecondaryOutcomeTimeFrame": "Week 0, 24 and 48"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nTalar chondral/osteochondral lesion confirmed by radiographical exam at screening or diagnosis, an AOFAS score of 75 or below\nAnkle joint pain/stiffness with no response to conservative treatment for more than 12 weeks\nAnkle joint cartilage injury of defect of ICRS grade Ⅳ\nMale or female aged more than 18\nA one-sided lesion\nAppropriate function of blood clot: PT(INR) < 1.5×ULN, aPTT <1.5×ULN\nAppropriate renal function: Creatinine ≤ 2.0 ㎎/㎗, Proteinuria ≤ trace\nAppropriate hepatic function: Total bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L\nNo evidence of auto-immune disorder: According to investigator's judgement based on relevent symtom and physical exam, anti-nuclear antibody and anti-thyroglobulin antibody tests are able to performed and confirmed negative (If positive, there are possible cases according to diagnostic opinion of medical department)\nNo surgery or radiotherapy for the same ankle joint within 6 weeks\n\nFemale patients agreeing with maintenance of contraception* during study period\n\n*hormone contraceptive, implants of intrauterine device or intrauterine system, double barrier contraception[Concurrent use of diaphragm or cervical occlusive cap and male condom], surgical sterilisation, etc.\n\nNo chronic ligament instability more than grade Ⅲ (Grade 0: none, Grade Ⅰ: 1~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜)\nPatients agreeing with participation in this study and signed on informed consent by their own will\n\nExclusion Criteria:\n\nDegenerative arthritis in ankle(Kellgren Lawrence Grade 3-4)\nAutoimmune disease\nInfectious disease need to administration of parenteral antibiotics\nMyocardial infarction, congestive heart failure, other serious cardiac disorder or uncontrolled resistant hypertension\n\nSerious medical disease(Ex. Kidney disease such as chronic renal failure or Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty liver etc., medical history of malignancy*)\n\n*Complete remission status is possible.\n\nPregnancy or breast-feeding\nPsychiatric history or epilepsy\nAlcohol abuse\nHeavy smoker\nChronic inflammatory disease such as rheumatoid arthritis\nParticipants other clinical trials within 4 weeks\nAdministration of immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks\nPatients with acute ligament injury and clinically significant chronic ligament instability\nPatients treated with surgery or cell therapy product for the same disease\nPatients with hypersensitivity or allergy history to bovine protein, hyaluronic acid and gentamicin\nOther inappropriate patients determined by the principal investigator",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Kyunghee University Medical Center",
            "LocationCity": "Seoul",
            "LocationState": "Dongdaemun-gu",
            "LocationZip": "02447",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Gangnam Severance Hospital",
            "LocationCity": "Seoul",
            "LocationState": "Gangnam-gu",
            "LocationZip": "06273",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Samsung Medical Center",
            "LocationCity": "Seoul",
            "LocationState": "Gangnam-gu",
            "LocationZip": "06351",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Korea University Guro Hospital",
            "LocationCity": "Seoul",
            "LocationState": "Guro-gu",
            "LocationZip": "08308",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Chungnam National University Hospital",
            "LocationCity": "Daejeon",
            "LocationState": "Jung-gu",
            "LocationZip": "35015",
            "LocationCountry": "Korea, Republic of"
          },
          {
            "LocationFacility": "Inha University Hospital",
            "LocationCity": "Incheon",
            "LocationState": "Jung-gu",
            "LocationZip": "22332",
            "LocationCountry": "Korea, Republic of"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No",
      "IPDSharingDescription": "IPD will not be shared to other researchers."
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "InterventionBrowseModule": {
      "InterventionBrowseLeafList": {
        "InterventionBrowseLeaf": [
          {
            "InterventionBrowseLeafId": "T63",
            "InterventionBrowseLeafName": "Astragalus",
            "InterventionBrowseLeafRelevance": "low"
          }
        ]
      },
      "InterventionBrowseBranchList": {
        "InterventionBrowseBranch": [
          {
            "InterventionBrowseBranchAbbrev": "HB",
            "InterventionBrowseBranchName": "Herbal and Botanical"
          },
          {
            "InterventionBrowseBranchAbbrev": "All",
            "InterventionBrowseBranchName": "All Drugs and Chemicals"
          }
        ]
      }
    }
  }
}